| Delaware         (State      of incorporation)                                                                                                                                                                                                                                                                                                                   | 36-3463683(I.R.S.      employer identification no.) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
|                 99 West Street, Suite      J                  Medfield,      Massachusetts                      (Address of principal executive offices) |  02052(Zip      Code)                          |

| Large      accelerated filer  | Accelerated      filer   |
|---------------------------------------|----------------------------------|
| Non-accelerated      filer    | Smaller      reporting company x |

----

----

----

----

----

----

| Listing      of United States Patents |
|---------------------------------------|
|                                  |   |   |
| Patent      Number                    |              Title |  Issue Date |
| 5,227,161                             | “Method      to Clean and Disinfect Pathogens on the Epidermis by Applying a      Composition Containing Peroxidase, Iodide Compound and      Surfactant” | July      13, 1993   |
| 5,370,815                             | “Viscous      Epidermal Cleaner and Disinfectant” | December      6, 1994  |
| 5,389,385                             | “Treatment      of Iodine Deficiency Diseases” | February      14, 1995  |
| 5,419,902                             | “Method      for Inactivating Pathogens” | May      30, 1995  |
| 5,589,198                             | “Treatment      of Iodine Deficiency Diseases” | December      31, 1996  |
| 5,629,024                             | “Method      of Forming an Iodine Based Germicide Composition” | May      13, 1997 |
|                                  |   |   |
| 5,639,481                             | “Method      for the Therapeutic Treatment of a Mammalian Eye” | June      17, 1997 |
|                                  |   |   |
| 5,648,075                             | “Iodine      Based Germicidal Composition” | July      15, 1997 |
|                                  |   |   |
| 5,772,971                             | “Iodine-Based      Microbial Decontamination System” | June      30, 1998 |
|                                  |   |   |
| 5,849,291                             | “Ophthalmic      Non-Irritating Iodine Medicament” | December      15, 1998 |
|                                  |   |   |
| 5,885,592                             | “Method      & Pharmaceutical Compositions for Oral Administration of Molecular      Iodine” | March      23, 1999   |
| 5,910,318                             | “Treatment      of Iodine Deficiency Diseases” | June      8, 1999  |
| 5,955,101                             | “Dry      Starch-Iodine Pharmaceutical Formulations” | September      21, 1999  |
| 5,962,029                             | “Iodine      Germicides that Continuously Generate Free Molecular Iodine”  | November      5, 1999 |
| 6,019,970                             | “Treatment      of Iodine Deficiency Diseases” | February      1, 2000  |
| Re      36,605                        | “Reissue      of 08/963,900 Method to Clean and Disinfect Pathogens”  | March      7, 2000 |
| 6,248,335                             | “Stabilized      Oral Pharmaceutical Composition Containing Iodide and Iodate”  | June      19, 2001 |
| 6,261,577                             | “Non-Staining      Topical Iodine Composition”  | July      17, 2001 |
| 6,432,426                             | “Non-Staining      Topical Iodine Composition and Method” | August      13, 2002 |

----

| Name                        | Age    | Position with theCompany                 |
|-----------------------------|--------|------------------------------------------|
|                        |   |                                     |
| Paul      C. Desjourdy      | 48     | President,      Chief Executive Officer, |
|                        |   | Chief      Financial Officer, General    |
|                        |   | Counsel,      Treasurer and Director     |
|                        |   |                                     |
| Jack      H. Kessler, Ph.D. | 59     | Chaiman      of the Board and Secretary  |

----

----

| ·   | conducting      preclinical and clinical trials; |
|--------------------|--------------------------------------------------|

| ·   | obtaining      required regulatory approvals of drug  candidates; |
|--------------------|-------------------------------------------------------------------|

| ·   | manufacturing      any resulting products; and |
|--------------------|------------------------------------------------|

| ·   | commercializing      any resulting products. |
|--------------------|----------------------------------------------|

----

----

----

----

|                | Fiscal 2009                   |                          | Fiscal 2008 |
|---------------------|-------------------------------|-------------------------------|-------------|
|                | High                          | Low                           |        | High | Low |
|                |                          |                          |        |   |   |
| First      quarter  | $    0.01 | $    0.01 |        | $   0.90 | $    0.46 |
| Second      quarter | 0.05                          |    0.01        |        | 0.80 |    0.03 |
| Third      quarter  | 0.07                          |    0.01        |        | 0.04 |    0.02 |
| Fourth      quarter | 0.17                          |    0.03        |        | 0.03 |    0.01 |

----

----

----

----

----

----

|                                                             |   |              |
|------------------------------------------------------------------|--------|-------------------|
|                                                             |   | December      31, |
|                                                             |   |              | 2009 |   |   | 2008 |   |
|                                                             |   |              |   |   |   |   |   |
| Assets                                                           |   |              |   |   |   |   |   |
|                                                             |   |              |   |   |   |   |   |
| Current      assets:                                             |   |              |   |   |   |   |   |
|    Cash and cash      equivalents                 |   | $                 | 14,712 |   | $ | 66,242 |   |
|    Inventory                                           |   |              | - |   |   | 30,085 |   |
| Prepaid      expenses                                            |   |              | 1,375 |   |   | 21,263 |   |
|                                                             |   |              |   |   |   |   |   |
|          Total current assets                     |   |              | 16,087 |   |   | 117,590 |   |
|                                                             |   |              |   |   |   |   |   |
| Equipment and leasehold      improvements,      net of           |   |              |   |   |   |   |   |
|         accumulated depreciation                       |   |              | 624 |   |   | 1,627 |   |
|                                                             |   |              |   |   |   |   |   |
| Other      assets:                                               |   |              |   |   |   |   |   |
|     Equity      Investments (Notes 2 and 10) |   |              | -  |   |   | -  |   |
| Patent      and trademark costs, net of accumulated              |   |              |   |   |   |   |   |
|        amortization                                         |   |              | 4,299 |   |   | 206,216 |   |
| Deposit                                                          |   |              | - |   |   | 2,364 |   |
|                                                             |   |              |   |   |   |   |   |
|                                                             |   | $                 | 21,010 |   | $ | 327,797 |   |

----

|                                                                                 |   |              |             |    |   |        |   |
|--------------------------------------------------------------------------------------|--------|-------------------|-------------|---------|--------|-------------|--------|
|                                                                                 |   | December      31, |
|                                                                                 |   |              | 2009        |    |   | 2008        |   |
|                                                                                 |   |              |        |    |   |        |   |
|  Liabilities and Stockholders’      Equity (Deficit)                      |   |              |        |
|                                                                                 |   |              |        |    |   |        |   |
| Current      liabilities:                                                            |   |              |        |    |   |        |   |
| Accounts      payable                                                                |   | $                 | 96,400      |    | $      | 63,014      |   |
| Accrued      clinical development expenses                                           |   |              | 112,765     |    |   | 112,765     |   |
| Other      current liabilities                                                       |   |              | 146,522     |    |   | -           |   |
|                                                                                 |   |              |        |    |   |        |   |
|          Total current liabilities                                    |   |              | 355,687     |    |   | 175,779     |   |
|                                                                                 |   |              |        |    |   |        |   |
| Commitments (Notes      6, 7 and 9)                                                  |   |              |        |    |   |        |   |
|                                                                                 |   |              |        |    |   |        |   |
| Stockholders’ equity      (deficit):                                           |   |              |        |    |   |        |   |
| Common      stock, Class A, par value $.001 per share, 93,750,000    shares          |   |              |        |    |   |        |   |
|        authorized, 28,723,340 and 16,473,340 shares issued and      outstanding |   |              |        |    |   |        |   |
|        as of December 31, 2009 and 2008, respectively                           |   |              | 28,723      |    |   | 16,473      |   |
| Convertible      common stock, Class B, par value $.001                              |   |              |        |    |   |        |   |
|        per share, 1,250,000 shares authorized and unissued                      |   |              | -           |    |   | -           |   |
| Preferred      stock, par value $.001 per share, 5,000,000 shares                    |   |              |        |    |   |        |   |
|        authorized and unissued                                                  |   |              | -           |    |   | -           |   |
| Additional      paid-in capital                                                      |   |              | 21,720,085  |    |   | 21,526,658  |   |
| Accumulated      deficit                                                             |   |              | (22,083,485 | )       |   | (21,391,113 | )      |
|                                                                                 |   |              |        |    |   |        |   |
|          Total stockholders' equity (deficit)                         |   |              | (334,677    | )  |   | 152,018     |   |
|                                                                                 |   |              |        |    |   |        |   |
|                                                                                 |   | $                 | 21,010      |    | $      | 327,797     |   |

----

|                                               |   |   |                             |   |   |       |   |
|-----------------------------------------------|--------|--------|----------------------------------|--------|--------|------------|--------|
|                                               |   |   | Year      EndedDecember      31, |   |
|                                          |   |   | 2009                             |   |   | 2008       |   |
|                                          |   |   |                             |   |   |       |   |
| Revenue:                                      |   |   |                             |   |   |       |   |
| Net      product sales                        |   | $      | 2,582                            |   | $      | 391        |   |
|                                          |   |   |                             |   |   |       |   |
|        Total revenues                    |   |   | 2,582                            |   |   | 391        |   |
|                                          |   |   |                             |   |   |       |   |
| Operating      expenses:                      |   |   |                             |   |   |       |   |
| Cost      of goods sold                       |   | $      | 1,485                            |   | $      | 740        |   |
| Research      and development costs           |   |   | -                                |   |   | 585,528    |   |
| General      and administrative expenses      |   |   | 693,555                          |   |   | 1,209,352  |   |
|                                          |   |   |                             |   |   |       |   |
|        Total operating expenses          |   |   | 695,040                          |   |   | 1,795,620  |   |
|                                          |   |   |                             |   |   |       |   |
| Loss from      operations                     |   |   | (692,458                         | )      |   | (1,795,229 | )      |
|                                          |   |   |                             |   |   |       |   |
| Interest      income                          |   |   | 86                               |   |   | 11,124     |   |
|                                          |   |   |                             |   |   |       |   |
| Net loss                                      |   | $      | (692,372                         | )      | $      | (1,784,105 | )      |
|                                          |   |   |                             |   |   |       |   |
| Basic and diluted net loss per      share of  |   |   |                             |   |   |       |   |
|   common      stock                      |   | $      | (0.03                            | )      | $      | (0.11      | )      |
|                                          |   |   |                             |   |   |       |   |
| Weighted average number of      common shares |   |   |                             |   |   |       |   |
|   outstanding - basic and      diluted   |   |   | 22,106,217                       |   |   | 16,342,589 |   |

----

|                                                                     |   |   | Common      Stock     |   |   |       |   |   |        |   |   |             |   |   |   |   |
|--------------------------------------------------------------------------|--------|--------|----------------------------|--------|--------|------------|--------|--------|-------------|--------|--------|-------------|--------|--------|--------|--------|
|                                                                          |   |   | $.001      Par Value  |   |   | Additional |   |   |        |   |   |             |   |   |   |   |
|                                                                          |   |   | Class      A          |   |   | Paid-in    |   |   | Accumulated |   |   |             |   |   |   |   |
|                                                                          |   |   | Shares                |   |   | Amount     |   |   | Capital     |   |   | Deficit     |   |   |        |   |   | Total |   |
|                                                                     |   |   |                       |   |   |       |   |   |        |   |   |        |   |   |   |   |   |   |   |
| Balance,      December 31, 2007                                          |   |   | 15,158,340                 |   | $      | 15,158     |   | $      | 20,645,933  |   | $      | (19,607,008 | )      |   |   |   | $ | 1,054,083 |   |
|          Issuance of Shares – Executive Stock Grant |   |   | 1,275,000                  |   |   | 1,275      |   |   | 636,225     |   |   | -           |   |   |   |   |   | 637,500 |   |
|          Issuance of Shares – Consultants           |   |   | 40,000                     |   |   | 40         |   |   | 30,760      |   |   | -           |   |   |   |   |   | 30,800 |   |
|          Stock Based Compensation                         |   |   | -                          |        |   | -          |   |   | 213,740     |   |   | -           |   |   |   |   |   | 213,740 |   |
|          Net loss for the year                            |   |   | -                          |   |   | -          |   |   | -           |   |   | (1,784,105  | )      |   |   |   |   | (1,784,105 | ) |
|                                                                     |   |   |                       |   |   |       |   |   |        |   |   |        |   |   |   |   |   |   |   |
| Balance,      December 31, 2008                                          |   |   | 16,473,340                 |   |   | 16,473     |   | $      | 21,526,658  |   | $      | (21,391,113 | )      |   |   |   | $ | 152,018 |   |
|          Issuance of Shares – Executive Stock Grant |   |   | 10,000,000                 |   |   | 10,000     |   |   | 90,000      |   |   | -           |   |   |   |   |   | 100,000 |   |
|          Issuance of Shares – Consultants           |   |   | 1,000,000                  |   |   | 1,000      |   |   | 9,000       |   |   | -           |   |   |   |   |   | 10,000 |   |
|          Issuance of Shares – Private Placement     |   |   | 1,250,000                  |   |   | 1,250      |   |   | 23,750      |   |   | -           |   |   |   |   |   | 25,000 |   |
|          Stock Based Compensation                         |   |   | -                          |   |   | -          |   |   | 70,677      |   |   | -           |   |   |   |   |   | 70,677 |   |
|          Net loss for the year                            |   |   | -                          |   |   | -          |   |   | -           |   |   | (692,372    | )      |   |   |   |   | (692,372 | ) |
|                                                                     |   |   |                       |   |   |       |   |   |        |   |   |        |   |   |   |   |   |   |   |
| Balance,      December 31, 2009                                          |   |   | 28,723,340                 |   | $      | 28,723     |   | $      | 21,720,085  |   | $      | (22,083,485 | )      |   |   |   | $ | (334,677 | )  |

----

|                                                                                                     |   |   |                             |   |   |       |    |
|-----------------------------------------------------------------------------------------------------|--------|--------|----------------------------------|--------|--------|------------|---------|
|                                                                                                     |   |   | Year      EndedDecember      31, |   |
|                                                                                                |   |   | 2009                             |   |   | 2008       |    |
| Cash flows from operating      activities:                                                          |   |   |                             |   |   |       |    |
|                                                                                                |   |   |                             |   |   |       |    |
| Net      loss                                                                                       |   | $      | (692,372                         | )      | $      | (1,784,105 | )       |
| Adjustments      to reconcile net loss to net cash used in                                          |   |   |                             |   |   |       |    |
|        operating activities:                                                                   |   |   |                             |   |   |       |    |
|          Stock-based compensation                                                    |   |   | 128,416                          |   |   | 851,240    |    |
|          Issuance of securities for services rendered                                |   |   | 52,261                           |   |   | 30,800     |    |
|          Depreciation and amortization                                               |   |   | 24,583                           |   |   | 35,236     |    |
|              Loss on impairment of patents                       |   |   | 178,337                          |   |   | 78,632     |    |
|              Loss of rental deposit                              |   |   | 2,364                            |   |   | -          |    |
|          Changes in operating assets and liabilities:                                |   |   |                             |   |   |       |    |
|            Inventory                                                       |   |   | 30,085                           |   |   | (30,085    | )       |
|            Prepaid expenses                                                |   |   | 19,888                           |   |   | 11,691     |    |
|            Accounts payable and other current liabilities                  |   |   | 179,908                          |   |   | (213,009   | )  |
|              Net cash used in operating activities               |   |   | (76,530                          | )      |   | (1,019,600 | )       |
|                                                                                                |   |   |                             |   |   |       |    |
| Cash flows from investing      activities:                                                          |   |   |                             |   |   |       |    |
|                                                                                                |   |   |                             |   |   |       |    |
| Patent      and trademark cost additions                                                            |   |   | -                                |   |   | (16,539    | )       |
|             Net cash used in investing activities                     |   |   | -                                |   |   | (16,539    | )       |
|                                                                                                |   |   |                             |   |   |       |    |
| Cash flows from financing      activities:                                                          |   |   |                             |   |   |       |    |
|                                                                                                |   |   |                             |   |   |       |    |
| Proceeds      from issuance of common stock and warrants                                            |   |   | 25,000                           |   |   | -          |    |
|             Net cash provided by financing activities                 |   |   | 25,000                           |   |   | -          |    |
|                                                                                                |   |   |                             |   |   |       |    |
| Net decrease in cash and      cash equivalents                                                 |   |   | (51,530                          | )      |   | (1,036,139 | )       |
|                                                                                                |   |   |                             |   |   |       |    |
| Cash and cash      equivalents,      beginning of period                                            |   |   | 66,242                           |   |   | 1,102,381  |    |
|                                                                                                |   |   |                             |   |   |       |    |
| Cash and cash      equivalents,      end of period                                                  |   | $      | 14,712                           |   | $      | 66,242     |    |
|  There      were no payments made for interest or income taxes during 2009 or      2008.  |   |   |                             |   |   |       |    |

----

| 1.         Description      ofBusiness andBasis ofPresentation | Symbollon      Pharmaceuticals, Inc. (formerly Symbollon Corporation) was formed to      develop and commercialize proprietary iodine-based products for infection      control and treatment in biomedical and bioagricultural      industries. The      success of future operations is subject to a number of risks similar to      those of other companies in the same stage of      development.  Principal among these risks are the Company’s      cumulative operating losses, no assurance of profitable future operations,      early state of market development, competition from substitute products or      larger companies, dependence on key personnel and the uncertainty of      additional future financing as needed. The      accompanying financial statements have been prepared in conformity with      accounting principles generally accepted in the United States of America,      which contemplate continuation of the company as a going      concern.  The Company had net losses of $692,372 and $1,784,105      and negative cash flows from operations of $76,530 and $1,019,600 for the      years ended December 31, 2009 and 2008, respectively.  At      December 31, 2009, the Company had an accumulated deficit of $22,083,485      and negative working capital of $339,600.  The Company does not      have adequate cash resources to continue our base      operations.  These factors raise substantial doubt about the      company’s ability to continue as a going concern. These financial      statements do not include any adjustments relating to the recoverability      and classification of recorded asset amounts, or amounts and      classification of liabilities that might be necessary should the Company      be unable to continue as a going concern and, therefore, be required to      realize the Company’s assets and discharge our liabilities in other than      the normal course of operations. The      ability of the Company to continue as a going concern is dependent upon      the Company’s ability to receive continued financial support from the      Company’s creditors, stockholders and external investors and to increase      sales of Iogen, the Company’s dietary supplement marketed to promote      breast health for women.  Management is actively seeking equity      and debt financing from external investors, and is attempting to increase      sales of Iogen.  The Company is also pursuing other strategic      options, including possible sales or licenses of its technology or a sale      or merger of the Company.  In December 2008, the Company      transferred certain intellectual property in exchange for an equity stake      in BioCide Pharma, Inc., a start-up company, and the assumption of      approximately $18,000 in debt (see footnote 10 below).  In      January 2010, the Company raised $75,000 in a private placement of      3,750,000 shares of common stock.  Failure to either obtain the      support of additional external investors to finance the Company’s      operations, increase sales of Iogen or execute the Company’s other      strategic options will cause us to cease operations in the near      future.   |
|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.         Summary      ofSignificantAccounting      Policies  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Use of    Estimates                                                                                              | The      preparation of financial statements in conformity with generally accepted      accounting principles requires management to make estimates and      assumptions that affect the reported amounts of assets and liabilities and      disclosure of contingent assets and liabilities at the date of the      financial statements and the reported amounts of revenues and expenses      during the reporting period.  Actual results could differ from      those estimates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Cash and CashEquivalents                                                                                    | Cash      and cash equivalents include short-term, highly liquid investments with      maturities of less than three months when acquired.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Concentration ofCredit Risks                                                                                     | In      2008, the Company launched Iogen as a dietary supplement for the promotion      of female breast health.  Currently, the Company is selling      Iogen through its website, www.BuyIogen.com.  Purchases of      Iogen are made through credit card transactions.  The Company      had no accounts receivables as of December 31, 2009 or 2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Inventory                                                                                                        | Inventory      is stated at the lower of cost (determined on a first-in, first-out basis)      or market.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Long-Lived    Assets                                                                                             | Long-lived      assets, such as intangible assets and property and equipment are evaluated      for impairment when events or changes in circumstances indicate that the      carrying amount of the assets may not be recoverable through the estimated      undiscounted future cash flows from the use of these      assets.  When any such impairment exists, the related assets are      written down to fair value.  In 2009 and 2008, the Company      performed an evaluation based on changes in events and circumstances      related to the Company’s ability to generate sufficient projected future      cash flows to cover the capitalized costs of certain      patents.  Based on the evaluation, the Company wrote off      $178,337 and $78,632, respectively, of impaired patent      costs.  The Company does not believe that any of its other      long-lived assets are impaired at December 31, 2009 or 2008.  |
| Depreciation andAmortization                                                                                     | Equipment      is stated at cost and is depreciated over its estimated useful life      (ranging from 5-7 years) using the straight-line method.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

----

| 2.         Summary      ofSignificantAccounting      Policies(Continued)  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intangible    Assets                                                                                                        | Intangible      assets subject to amortization consist of patents and trademarks that have      estimated useful lives ranging from 9-17 years and a weighted average      remaining useful life of 5.9 years.  Costs related to patent      applications are capitalized as incurred and are amortized once the patent      application is accepted or are expensed if the application is rejected or      there are other circumstances that indicate that the asset is impaired (as      described above).  |
| Income Taxes                                                                                                                | The      Company follows the liability method of accounting for income      taxes.  Under this method, deferred tax liabilities and assets      are recognized for the expected future tax consequences of temporary      differences between the carrying amount and the tax basis of assets and      liabilities.  The Company records a valuation allowance against      deferred tax assets unless it is more likely than not that such asset will      be realized in future periods.           |
| Fair value ofFinancialInstruments                                                                                      | The      carrying amounts of cash and cash equivalents, other current assets and      accounts payable approximate fair value based on their short-term      maturities.                                                                                                                                                                                                                                                                                                                                                 |
| EquityInvestment                                                                                                            | On      December 8, 2008, the Company acquired 625,000 shares of common stock in      BioCide Pharma, Inc., a start-up venture, in exchange for a transfer of      certain patent rights and assumption of liabilities.  The      Company accounts for this investment on the equity method.  At      December 31, 2009 and 2008, the Company’s investment had no recorded      value.                                                                                                         |
| RevenueRecognition                                                                                                          | The      Company recognizes revenue from its product sales and licensing      arrangements in accordance with SEC guidelines.  Under these      guidelines, revenue is recognized when persuasive evidence of an      arrangement exists, delivery has occurred or services rendered, the price      is fixed or determinable and payment is reasonably  assured.                                                                                                                                                   |

----

| 2.         Summary      ofSignificantAccounting      Policies(Continued)  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Research andDevelopment                                                                                                | Research      and development costs are expensed as incurred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Stock-BasedCompensation                                                                                                | The      Company accounts for share-based compensation based on the option’s fair      value and the vesting period of the award.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Loss Per Share                                                                                                              | Basic      earnings per share excludes the effect of any dilutive options, warrants      or convertible securities and is computed by dividing the net earnings      available to common shareholders by the weighted average number of common      shares outstanding for the period.  Diluted earnings per share      is computed by dividing the net earnings available to common shareholders      by the sum of the weighted average number of common shares and common      share equivalents computed using the average market price for the period      under the treasury stock method.  |
| Adoption of      WarrantAccounting                                                                                     | In      June 2008, FASB issued guidance for determining whether an equity-linked      financial instrument (or embedded feature) is indexed to an entity’s own      stock. This guidance applies to any freestanding financial instrument or      embedded feature that has all the characteristics of a derivative. This      guidance is effective for fiscal years beginning after December 15,      2008.  We have concluded that adoption of this guidance on      January 1, 2009 did not have a material impact on the Company’s financial      statements.                    |
| 3.         Equipment      andLeaseholdImprovements                             | Equipment      and leasehold improvements are stated at cost and consist of the      following:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

| December      31,                              | 2009                                                 | 2008                                                   |
|------------------------------------------------|------------------------------------------------------|--------------------------------------------------------|
|                                           |                                                 |                                                   |
| Equipment      and fixtures                    | $   30,710                            | $    161,610                       |
| Leasehold      improvements                    | -                                                    | 63,146                                                 |
|                                           |                                                 |                                                   |
|                                           | 30,710                                               | 224,756                                                |
|                                           |                                                 |                                                   |
|  Less      accumulated depreciation       | 30,086                                               | 223,129                                                |
|                                           |                                                 |                                                   |
| Equipment      and leasehold improvements, net | $        624 | $        1,627 |

|   | Depreciation      expense for the years ended December 31, 2009 and 2008 totaled $1,003 and      $1,133, respectively.  |
|--------|------------------------------------------------------------------------------------------------------------------------------|

----

| 4.         Patent      andTrademarkCosts | Patent      and trademark costs consist of the following:  |
|---------------------------------------------------------------------------------------|-----------------------------------------------------------------|

| December      31,                         | 2009                                 | 2008                                   |
|-------------------------------------------|--------------------------------------|----------------------------------------|
|                                      |                                 |                                   |
| Patent      costs                         | $    10,872      | $    314,910       |
| Trademark      costs                      | 2,444                                | 2,444                                  |
|                                      |  13,316                         |  317,354                          |
|  Less      accumulated amortization  |  9,017                          |  111,138                          |
|  Patent      and trademark cost, net |  $    4,299 |  $    206,216 |

|                                                                                                                                                                      | Amortization      expense related to these assets is estimated to be approximately $725 per      year in fiscal years 2010 through 2016.  Amortization expense      for the years ended December 31, 2009 and 2008 totaled $23,580 and      $34,103, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.         Stockholders’Equity                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Capital Stock                                                                                                                                                             | The      Company has authorized 93,750,000 shares of Class A common stock,      1,250,000 shares of Class B common stock and 5,000,000 shares of      preferred stock.  The Class A and Class B common stock      are substantially identical except that holders of Class A common      stock have the right to cast one vote for each share held and the      Class B shareholders have the right to cast five votes for each share      held.  As of December 31, 2009 and 2008, there were no      shares of Class B common stock issued and outstanding.  The      preferred stock may be issued in series, and shares of each series will      have such rights and preferences as are fixed by the Company’s Board of      Directors.  As of December 31, 2009 and 2008, there were no      shares of preferred stock issued and outstanding.  |
| Issuance of CommonStock and Common         Stock      Purchase         Warrants | The      Company has recognized $52,261 and $30,800 of expense related to certain      of the shares and warrants issued for services for the years ended      December 31, 2009 and 2008, respectively, in the accompanying statements      of operations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

----

| 5.         Stockholders’Equity(Continued)                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Issuance of CommonStock and Common         Stock      Purchase         Warrants(Continued) | On      January 18, 2008, the Company entered into a services agreement with The      Number One Corporation.  In accordance with the services      agreement, and as partial consideration for the services provided by the      vendor, the Company agreed to issue 40,000 shares of Class A common stock      upon execution of the agreement.  The Company has determined the      fair value of the shares to be $30,800 which was recognized as an expense      in general and administrative expenses in the accompanying statement of      operations for the year ended December 31, 2008.  No expense      related to these shares was recognized for the year ended December 31,      2009. On      February 7, 2008, the Company issued 900,000 and 375,000 restricted shares      to its executive officers, Messrs. Desjourdy and Kessler,      respectively.  The shares were initially to vest one-third each      of the next three anniversaries of the grant date.  On May 16,      2008, the Company fully vested the shares as part of the termination of      the executive officers’ employment agreements.  The Company      recorded $637,500 of stock-based compensation for the year ended December      31, 2008, with $450,000 and $187,500 included in general and      administrative expenses and in research and development costs,      respectively.  No expense related to these shares was recognized      for the year ended December 31, 2009. On      June 29, 2009, the Company issued 10,000,000 shares to its executive      officer, Mr. Desjourdy and 1,000,000 shares to certain      consultants.  The Company recorded $110,000 of stock-based      compensation for the year ended December 31, 2009 as general and      administrative expenses. On      December 24, 2009, the Company sold in a private placement to accredited      investors an aggregate of 1,250,000 shares of Class A common stock for net      proceeds of $25,000 in cash.  On January 11, 2010, the Company      sold in a private placement to accredited investors an aggregate of      3,750,000 shares of Class A common stock for net proceeds of $75,000 in      cash. At      December 31, 2009, warrants to purchase 7,293,732 shares of common stock      are outstanding.  |

----

| 6.         Stock      Plans  | The      Company has adopted two stock plans:  a stock option plan and a      nonemployee directors’ stock option plan. The      stock option plan provides for the grant of incentive stock options,      nonqualified stock options and stock appreciation rights.  The      stock option plan expired on August 4, 2008 with options to purchase      1,225,000 shares outstanding at December 31, 2009.  No future      grants may be made under this plan. On      May 24, 2006 the Company adopted a 2006 nonemployee directors’ stock      option plan that provides for the grant of nonstatutory stock options      automatically on January 1 of each calendar year commencing on      January 1, 2007.  The Company has reserved 500,000 shares      for issuance under the plan.  Each outside director shall be      granted an option to purchase 10,000 shares of Class A common stock      at fair market value, vesting 50% on each of the first two anniversaries      of the grant.  The nonemployee directors’ stock option plan      expires on the first business day of 2017.  Under the this plan      400,000 shares are available for future grant.  |
|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.         Stock      Plans(Continued) | Through      December 31, 2008 the Company issued stock options to its employees and      outside directors pursuant to stockholder-approved stock option      plans.  On October 1, 2009 the Company issued stock options to      its outside directors outside of a stockholder-approved stock option      plan.  Option awards are generally granted with an exercise      price equal to the market price of the Company’s stock at the date of      grant.  Employee option awards generally vest over three years      from the date of grant, and outside directors option awards generally vest      over two years from the date of grant.  All option awards      generally have 10-year contractual terms.  The Company      attributes stock-based compensation cost to operations using the      straight-line method over the applicable vesting period. The      Company recorded $170,678 and $213,740 of stock-based compensation for the      years ended December 31, 2009 and 2008, respectively, in general and      administrative expenses.  As of December 31, 2009 the      unrecognized stock-based  compensation cost related to      non-vested stock awards was $51,317.  This amount will be      recognized in operations over a weighted average period of 12      months. The      following table summarizes the Company’s stock option information as of,      and for the year ended December 31,2009: |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                                 |   Number      ofShares |  WeightedAverageExercisePrice                    | Weighted      AverageRemainingContractualTerm |   AggregateIntrinsicValue      (1) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------------------|-----------------------------------------------|----------------------------------------------|
|                                                                                                                                                                                 |                             |                                                  |                                          |                                         |
| Outstanding      at December 31, 2008                                                                                                                                                | 1,345,000                        | $       0.90       |                                          |                                         |
|    Options      granted                                                                                                                                               |  2,040,000                  |  $       0.03 |                                          |                                         |
|   Options      expired                                                                                                                                                     | (7,500)                          | $       1.60       |                                          |                                         |
|  Outstanding      at December 31, 2009                                                                                                                                          |  3,377,500                  |  $       0.37 |  8.5                                     |  $286,000                               |
|  Exercisable      at December 31, 2009                                                                                                                                          |  1,247,500                  |  $       0.93 |  6.6                                     |  $0                                     |
|  (1)  The      intrinsic value of a stock option is the amount by which the current      market value of the underlying stock exceeds the option exercise      price. |

----

| 6.         Stock      Plans(Continued) | For      the years ended December 31, 2009 and 2008, the Company granted options      for 2,040,000 and 180,000 shares exercisable between $0.01 and $0.65 per      share.  The weighted-average grant date fair value of stock      options granted during the years ended December 31, 2009 and 2008 was      $0.03 and $0.39 per share, respectively.  No stock options were      exercised during the years ended December 31, 2009 or 2008.  |
|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                | The      fair value of each option granted was estimated on the date of grant using      the Black-Scholes option-pricing model with the following      assumptions:                                                                                                                                                                                                                                                                                                       |

|                                                             |   | Year      EndedDecember      31, |
|------------------------------------------------------------------|--------|----------------------------------|
|                                                             |   | 2009                             | 2008 |
|                                                             |   |                             |   |
| Weighted-average      expected stock-price  volatility |   | 143-145%                         | 88% |
|                                                             |   |                             |   |
| Weighted-average      expected option life                       |   | 6      years                     | 6      years |
|                                                             |   |                             |   |
| Average      risk-free interest rate                             |   | 1.72-2.20%                       | 2.79-3.28% |
|                                                             |   |                             |   |
| Average      dividend yield                                      |   | 0.0%                             | 0.0% |

|   | The      dividend yield of zero is based on the fact that the Company has never      paid cash dividends and has no present intention to pay cash      dividends.  Expected volatility is based on the historical      volatility of the Company’s common stock over the period commensurate with      the expected life of the options.  The risk-free interest rate      is the U.S. Treasury Strips rate on the date of grant.  The      expected life was calculated using the 0.0% simplified method as the      Company’s historical experience does not provide a reasonable basis for      the expected term of the option.  Based on the recent history      and current expectations, the Company has not adjusted the calculated      value of the options for the year ended December 31, 2009 to reflect a      forfeiture rate. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | All      options outstanding at December 31, 2009 are expected to vest and are      categorized by the following ranges in the table  below: |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|

|    SharePrice      Range |  Weighted-AverageExercisePrice | Weighted-AverageRemainingContractualLife      (years) |    Number      ofShares |
|-----------------------------------------|-------------------------------------|-------------------------------------------------------|----------------------------------------|
| $0.21      to $1.00                     | $0.83                               | 8.7                                                   | 3,280,000                              |
| $1.00      to $3.63                     | $1.80                               | 3.6                                                   | 97,500                                 |
|                                    |                                |                                                  |  3,377,500                        |

----

|   | All      options exercisable at December 31, 2009 are categorized by the      following ranges in the tablebelow: |
|--------|------------------------------------------------------------------------------------------------------------------------|

|    SharePrice      Range |  Weighted-AverageExercisePrice | Weighted-AverageRemainingContractualLife      (years) |    Number      ofShares |
|-----------------------------------------|-------------------------------------|-------------------------------------------------------|----------------------------------------|
| $0.21      to $1.00                     | $0.85                               | 6.9                                                   | 1,150,000                              |
| $1.00      to $3.63                     | $1.82                               | 3.6                                                   | 97,500                                 |
|                                    |                                |                                                  |  1,247,500                        |

|                                                                        | The      weighted-average fair value of options granted during the years ended      December 31, 2009 and 2008 was $0.03 and $0.53 per share,      respectively.                                                                                                 |
|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7.         Loss      Per Share | The      Company’s basic and diluted net loss per share of common stock for the      years ended December 31, 2009 and 2008 is computed by dividing the      net loss by the weighted average number of common shares outstanding      during the period.  |
|                                                                        | The      following table summarizes securities that were outstanding as of      December 31, 2009 and 2008 but not included in the calculation of      diluted net loss per share because such shares are      antidilutive:                                          |

| December      31,   | 2009      | 2008      |
|---------------------|-----------|-----------|
|                |      |      |
| Stock      options  | 3,377,500 | 1,345,000 |
| Stock      warrants | 7,293,732 | 7,879,193 |

----

| 8.         Income      Taxes | The      following table summarizes the significant differences between the benefit      that would be recognized under the United States federal statutory tax      rate and the Company’s effective tax rate for financial statement      purposes: |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| December      31,                                                    | 2009           | 2008           |
|----------------------------------------------------------------------|----------------|----------------|
|                                                                 |           |           |
| United      States federal statutory tax rate                        | 34%            | 34%            |
| State      taxes, net of United States                               |           |           |
|    federal      tax benefit                           | 6%             | 6%             |
|                                                                 |           |           |
| Valuation      allowance provided against net                        |           |           |
|    operating      loss carry forwards and tax credits | (40%)          | (40%)          |
|                                                                 |           |           |
| Effective      tax rate                                              | -  % | -  % |

|   | Deferred      income taxes reflect the impact of “temporary differences” between the      amount of assets and liabilities for financial reporting purposes and such      amounts as measured by tax laws and regulations.  Deferred tax      assets are comprised of thefollowing: |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| December      31,                     | 2009                                                                                                     | 2008                                                                                                     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|                                  |                                                                                                     |                                                                                                     |
| Tax      credit carryforwards         | $      653,000                                                             | $      685,000                                                             |
| Net      operating loss carryforwards | 6,830,000                                                                                                | 7,268,000                                                                                                |
|                                  |                                                                                                     |                                                                                                     |
| Gross      deferred tax asset         | 7,483,000                                                                                                | 7,953,000                                                                                                |
|                                  |                                                                                                     |                                                                                                     |
| Deferred      tax assets valuation    |                                                                                                     |                                                                                                     |
|   allowance                 | (7,483,000)                                                                                              | (7,953,000)                                                                                              |
|                                  |                                                                                                     |                                                                                                     |
| Net      deferred tax assets          | $                 - | $                 - |

----

| 8.         Income      Taxes(Continued) | As      of December 31, 2009 and 2008, the deferred tax assets have been      fully offset by valuation allowances, since the realization of such      amounts is uncertain.  The change in the valuation allowance      during 2009 and 2008 was $470,000 and $87,000, respectively. As      of December 31, 2009, the Company has net operating loss      carryforwards totaling approximately $17,074,000.  The amount of      the net operating loss carryforwards which may be utilized in any future      period may be subject to certain limitations, based upon changes in the      ownership of the Company’s common stock.  |
|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                 | The      following is a breakdown of the net operating loss expiration      period:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

|                 | Amount      of                                 |
|----------------------|------------------------------------------------|
| Expiration      Date | Remaining      NOL                             |
|                 |                                           |
| 2010                 | $      1,374,000 |
| 2011                 | 921,000                                        |
| 2018                 | 897,000                                        |
| 2019                 | 739,000                                        |
| 2020                 | 476,000                                        |
| 2021                 | 1,387,000                                      |
| 2022                 | 612,000                                        |
| 2023                 | 638,000                                        |
| 2024                 | 2,061,000                                      |
| 2025                 | 953,000                                        |
| 2026                 | 2,319,000                                      |
| 2027                 | 3,330,000                                      |
| 2028                 | 840,000                                        |
| 2029                 | 527,000                                        |
|                 |                                           |
|                 | $      17,074,000                              |

|   | In      addition, the Company has available tax credit carryforwards (adjusted to      reflect provisions of the Tax Reform Act of 1986) of approximately      $653,000, which are available to offset future taxable income and income      tax liabilities, when earned or incurred.  These amounts expire      in various years through 2029.  The amount of the tax credit      carryforwards which may be utilized in any future period may be subject to      certain limitations, based upon changes in the ownership of the Company’s      common stock. The      Company files income tax returns in the U.S. federal jurisdiction and in      several state jurisdictions. For U.S. federal and state tax purposes, the      tax years 2006 through 2009 remain open to examination.  In      addition, the amount of the Company’s federal and state net operating loss      carryforwards may be subject to examination and  adjustment. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.         Commitments  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Facilities    Lease                                                       | The      Company leases its facilities on a month-to-month basis.  Rent      expense for the years ended December 31, 2009 and 2008 was      approximately $35,700 and $42,300, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| EmploymentAgreements                                                      | On      January 3, 2006, the Company entered into employment agreements with its      principal officers providing for minimum base compensation and severance      pay which expire December 31, 2008.  On February 7, 2008,      the Company entered into an amendment to those employment agreements with      its principal officers extending the expiration of the agreements to      December 31, 2011.   On May 16, 2008, the Company modified      those employment agreements with with its principal officers to limit      their term from December 2011 to June 2008.  The Company agreed      to cover health insurance benefits for 12 months following the termination      of the employment agreements.  After the termination of his      current employment agreement, Mr. Desjourdy was employed by the Company in      his current positions at $18,000 per month on a month-to-month      basis.  For the years ended December 31, 2009 and 2008, the      aggregate amount paid to the Company’s principal officers was $226,000 and      $345,250, respectively.  |
| Royalty    Agreement                                                      | A      royalty agreement with one of the inventors who assigned certain patent      rights to the Company provides for royalties based on a percentage of the      licensing revenues received by the Company from products falling within      the scope of the patent rights.  The percentage varies from 1.5%      to 5% depending on the gross revenues received, with maximum royalty      payments under the agreement not to exceed $2,884,000.  Through      December 31, 2009, no royalties have been earned under this      agreement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

----

| 9.         Commitments(Continued)           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ConsultingAgreements                                                                          | The      Company has entered into various scientific advisory and consulting      agreements to support its development activities.  These      agreements generally expire over several future years.  Amounts      charged to operations in connection with these agreements for the years      ended December 31, 2009 and 2008 amounted to approximately $53,000      and $128,000, respectively.                                                                                                                                                                                                                                                                  |
| Finder’s Fees                                                                           | The      Company has entered into agreements to pay finders’ fees for agreements      entered into with certain companies for investment or revenue      purposes.  The finders’ fees are based on a percentage of the      investment or revenue.  No amounts were paid or accrued pursuant      to any of these agreements during 2009 or 2008.                                                                                                                                                                                                                                                                                                               |
| Employee BenefitPlan                                                                          | Effective      January 1, 2007, the Company established a 401(k) plan covering its      employees.  The Company makes contributions to the plan at the      discretion of the Board of Directors based upon a percentage of employee      compensation as provided by the terms of the plan.  The Company      made contributions of $3,589 to the plan equal to 3% of employee salaries      for the first three months of the year ended December 31, 2008, and      thereafter, the Company ceased making contributions to the      plan.                                                                                                                                |
| 10.         Related      PartyTransactions  | A      member of the Board of Directors provides legal services to the      Company.  Amounts paid for legal services rendered by the      director, either individually or through his firm, totaled $9,638 and      $26,294 for the years ended December 31, 2009 and 2008,      respectively. The      Company exchanges office space for services with a company owned by the      spouse and in-law of one of the Company’s officers and      directors.  The officer and director is also a director in the      other company.  The estimated annual value for 2009 and 2008 of      the relationship is $6,400 and $9,600, respectively.  |
|                                                                                          | On      December 8, 2008 the Company signed a sale/license agreement with BioCide      Pharma, Inc. covering upper respiratory tract products based on the      Company’s proprietary iodine-based technology.  Under the      agreement, the Company transferred ownership of its patent application      covering use of its technology in the upper respiratory tract and granted      an exclusive license to its other iodine-based technology for use in the      field.  As partial consideration under the agreement, the      Company received 625,000 shares of common stock in BioCide which      represents 50% ownership of the company.                 |

----

| 10.         Related      PartyTransactions(Continued)  | Additionally,      BioCide agreed to assume all of the Company’s outstanding patent fees and      expenses (approximately $18,000) related to the patent      application.  Under the agreement, BioCide is required to raise      an aggregate of $1,250,000 in third party funding by the end of      2010.  So long as the Company retains at least a 10% ownership      position in BioCide, it has the right to appoint one member of BioCide’s      board of directors.  Two members of the Company’s Board of      Directors own the remaining outstanding equity of BioCide, and are also      officers and directors of BioCide.  As part of the transaction,      one of the directors loaned BioCide $50,000 in order for BioCide to cover      currently due patent prosecution expenses related to the transferred      patent application.  Due to the uncertainty as to the      recoverability of the assets received and its related party nature, no      value has been assigned to the assets.  |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11.         SubsequentEvents                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Private PlacementOf Securities                                                                           | On      January 11, 2010, the Company sold in a private placement to accredited      investors an aggregate of 3,750,000 shares of Class A common stock for net      proceeds of $75,000 in cash. The      Company evaluated all events or transactions that occurred after December      31, 2009 through the date of this Annual Report.  The Company      determined that it did not have any other subsequent events through March      31, 2010, which is the date the financial statements were issued,      requiring recording or disclosure in the financial statements for the year      ended December 31, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                              |

----

|   | Item      9.  Changes in and Disagreements with Accountants on Accounting      and Financial Disclosure |
|--------|-------------------------------------------------------------------------------------------------------------------|

----

----

| Signature                   | Title                                    |        Date |
|-----------------------------|------------------------------------------|------------------------------------------------|
|                        |                                     |                                           |
| /s/      Paul C. Desjourdy  | President,      Chief Executive Officer, | March      31, 2010                            |
| Paul      C. Desjourdy      | Treasurer,      Chief Financial Officer, |                                           |
|                        | General      Counsel, and Director       |                                           |
|                        | (Principal      Executive, Financial     |                                           |
|                        | and      Accounting Officer)             |                                           |
|                        |                                     |                                           |
|                        |                                     |                                           |
| /s/      Jack H. Kessler    | Chairman      of the Board of Directors  | March      31, 2010                            |
| Jack      H. Kessler        | and      Secretary                       |                                           |
|                        |                                     |                                           |
|                        |                                     |                                           |
|                        |                                     |                                           |
| /s/      James C. Richards  | Director                                 | March      31, 2010                            |
| James      C. Richards      |                                     |                                           |
|                        |                                     |                                           |
| /s/      Richard F. Maradie | Director                                 | March      31, 2010                            |
| Richard      F. Maradie     |                                     |                                           |
|                        |                                     |                                           |
| /s/      Eugene Lieberstein | Director                                 | March      31, 2010                            |
| Eugene      Lieberstein     |                                     |                                           |

----

| 3.1 | Amended      Certificate of Incorporation of the Company. (previously filed as exhibit      3.1 to Form 10-KSB for the year ended December 31, 2005 and incorporated      by reference) |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | Amended      By-Laws of the Company. (previously filed as exhibit 3.2 to Form 10-QSB      for the quarter ended June 30, 1999 and incorporated by      reference) |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3 | Agreement      of Merger, dated as of August 4, 1993, between the Company and Symbollon      Corporation, a Massachusetts corporation (including Certificate of Merger      and other state filings). (previously filed as exhibit number 3.3 of the      Registration Statement (the “Registration Statement”) on Form SB-2      (Registration No. 33-68828) filed on November 24, 1993 and declared      effective on December 7, 1993, and incorporated by    reference) |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1 | Form      of Specimen Class A Common Stock Certificate. (previously filed as exhibit      number 4.2 of the Registration Statement and incorporated by      reference) |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.1 | 1993      Stock Option Plan of the Company, as amended. (incorporated by reference      to Exhibit C to the Company’s 2005 Annual  Stockholders Meeting      Proxy Statement filed under cover of Schedule 14A dated May 4,      2005) |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | Form      of Indemnification Agreement between the Company and each officer and      director of the Company. (previously filed as exhibit number 10.6 of the      Registration Statement and incorporated by  reference) |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | Agreement,      dated August 31, 1992, among the Company, Dr. Jack H. Kessler and Dr.      Robert Rosenbaum. (previously filed as exhibit number 10.8 of the      Registration Statement and incorporated by  reference) |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4 | Form      of Stock Option Agreement to be entered into between the Company and each      option holder. (previously filed as exhibit number 10.10 to Form 10-KSB      for the year ended December 31, 1993 and incorporated by      reference) |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.5 | 2006      Non-Employee Directors’ Stock Option Plan of the Company. (previously      filed as exhibit number 10.1 to Form 8-K filed on May 30, 2006 and      incorporated by reference) |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.6 | 1995      Non-Employee Directors’ Stock Option Plan of the Company. (previously      filed as exhibit number 10.1 to Form 10-QSB for the quarter ended June 30,      1995 and incorporated by reference) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.7 | Form      of Warrant for the purchase of shares of Class A Common Stock, dated as of      February 28, 2006, issued to certain purchasers of the Company’s      securities (previously filed as an exhibit number 10.1 to Form 8-K filed      on March 7, 2006 and incorporated byreference) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.8 | Form      of Warrant for the purchase of shares of Class A Common Stock, dated as of      February 28, 2006, issued to certain purchasers of the Company’s      securities (previously filed as exhibit number 10.1 to Form 8-K filed on      March 7, 2006 and incorporated byreference) |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.9 | Securities      Purchase Agreement, dated as of June 2, 2006, between Symbollon and      certain purchasers of Symbollon’s securities. (previously filed as exhibit      number 10.1 to Form 8-K filed on June 7, 2006 and incorporated by      reference) |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.10 | Form      of Redeemable Warrant expiring on June and August 2011 for the purchase of      shares of Class A common stock issued to certain purchasers of Symbollon’s      securities. (previously filed as exhibit number 10.2 to Form 8-K filed on      June 7, 2006 and incorporated byreference) |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.11 | Registration      Rights Agreement, dated as of June 2, 2006, between Symbollon and certain      purchasers of Symbollon’s securities. (previously filed as exhibit number      10.3 to Form 8-K filed on June 7, 2006 and incorporated by      reference) |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.12 | Form      of Redeemable Warrant expiring December 2011 for the purchase of shares of      Class A common stock issued to certain purchasers of Symbollon’s      securities. (previously filed as exhibit number 10.22 to the Registration      Statement on Form SB-2 (Registration No. 333-140200) filed on January 25,      2007 (the “2007 Registration Statement”) and declared effective on      February 7, 2007, and incorporated byreference) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.13 | Form      of Subscription Agreement, dated as of December 29, 2006, between      Symbollon and certain purchasers of Symbollon’s securities. (previously      filed as exhibit number 10.23 to the 2007 Registration      Statement) |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.14 | Securities      Purchase Agreement, dated as of September 27, 2007, between Symbollon and      certain purchasers of Symbollon’s securities (previously filed as exhibit      number 10.1 to Form 10-QSB for the quarter ended September 30, 2007 and      incorporated by reference) |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.15 | Form      of Subscription Agreement, dated as of September 27, 2007, between      Symbollon and certain purchasers of Symbollon’s securities (previously      filed as exhibit number 10.2 to Form 10-QSB for the quarter ended      September 30, 2007 and incorporated by  reference) |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.16 | Form      of Redeemable Warrant expiring on September 2012 for the purchase of      shares of Class A common stock issued to certain purchasers of Symbollon’s      securities (previously filed as exhibit number 10.3 to Form 10-QSB for the      quarter ended September 30, 2007 and incorporated by      reference) |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.17 | Registration      Rights Agreement, dated as of September 27 2007, between Symbollon and      certain purchasers of Symbollon’s securities (previously filed as exhibit      number 10.4 to Form 10-QSB for the quarter ended September 30, 2007 and      incorporated by reference) |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 31.1 | Certification      of the Chief Executive Officer and Chief Financial Officer required by      Securities Exchange Act Rule 13a-14(a) as adopted pursuant to      Section 302 of the Sarbanes-Oxley Act of 2002.  * |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 32.1 | Certification      of the Chief Executive Officer and Chief Financial Officer required by      Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350, as      adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.      * |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| * | Filed      herewith. |
|---|----------------------|

----